Neuronetics publishes significant real-world findings on NeuroStar TMS treatment effects.

Neuronetics Inc. has published a study in the Journal of the American Academy of Child & Adolescent Psychiatry Open, showing antidepressant effects in adolescent and young adult patients treated with NeuroStar TMS. The results are consistent with those previously reported in adults. The company has seen a one-third increase in adolescents being treated with the therapy since receiving FDA clearance in March 2024.

Neuronetics Inc. (NASDAQ: STIM) has published a significant study in the Journal of the American Academy of Child & Adolescent Psychiatry Open (JAACAP Open), highlighting the antidepressant effects of NeuroStar TMS (transcranial magnetic stimulation) in adolescent and young adult patients. The results, which were consistent with those previously reported in adult populations, demonstrated strong treatment efficacy.

The study, based on the world's largest TMS outcomes dataset, analyzed 1,283 patients aged 12-21 and found that approximately 70% of patients showed clinically meaningful improvement. This efficacy profile mirrors results previously seen in adult populations, establishing consistency across age groups and reinforcing the technology's therapeutic value. The study used the Patient Health Questionnaire-9 (PHQ-9) to measure depression symptoms, with less than 1% of patients experiencing clinically meaningful worsening.

Since receiving FDA clearance in March 2024 for treating adolescents aged 15-21, NeuroStar has seen a one-third increase in adolescent treatments. This rapid adoption reflects the significant unmet need, with 20% of adolescents experiencing major depressive disorder and limited treatment options currently available. The adolescent market represents a strategic growth opportunity for Neuronetics, especially considering the limited pharmaceutical options for this demographic, both carrying significant safety warnings.

The publication of real-world data in JAACAP Open represents a significant clinical validation for Neuronetics' NeuroStar TMS system in treating adolescent depression. The company's proprietary TrakStar database continues to provide valuable real-world evidence that supports both clinical acceptance and payer discussions.

Neuronetics' clinical data confirms NeuroStar TMS efficacy in adolescents, supporting market expansion following recent FDA clearance. The company is engaging with providers and payers to expand reimbursement coverage, which will be crucial for broader market adoption in this newly approved indication.

References:
1. [1] https://www.globenewswire.com/news-release/2025/07/30/3124076/0/en/NeuroStar-Announces-New-Publication-in-JAACAP-Open-Highlighting-Treatment-Efficacy-in-Depressed-Adolescents.html
2. [2] https://www.stocktitan.net/news/STIM/neuro-star-announces-new-publication-in-jaacap-open-highlighting-8874vsjeikx4.html